Trial Profile
An Open-Label Safety and Efficacy Study of an Anti-CD20 Antibody (Rituximab, Rituxan) for Anti-B Cell Therapy in the Treatment of Systemic Lupus Erythematosus
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Systemic lupus erythematosus
- Focus Pharmacodynamics; Therapeutic Use
- 01 Feb 2013 New trial record